ClinicalTrials.gg
Not yet recruitingNCT07681713PROVE-FAUpdated Aug 14, 2026

Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)

A Phase 3 interventional study of Vatiquinone in Friedreich's Ataxia, sponsored by PTC Therapeutics. Not yet recruiting at 9 sites in 6 countries. Open to participants aged 7 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by PTC Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
7 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Friedreich Ataxia with a site in United States — 18 open to participants now, 25 under way, 4 of them phase 3. Friedreich Ataxia · United States.

Planned enrollment
6th of 49
120 · median 32
Started
2026
with 7 others
Phase 3
10 of 71
2 open now
Primary completion
2029-03
later than 14 of 24 live
Registered
67th of 71
by date
Lead sponsor
6 of 71
PTC Therapeutics

Among the 71 studies in Friedreich Ataxia with a site in United States, this one is the 6th largest by planned enrollment of the 49 interventional ones that give a count, is one of 8 that started in 2026, is one of 10 in phase 3, reaches primary completion later than 14 of the 24 other live ones, and was the 67th registered.

Friedreich Ataxia

111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.

Browse Friedreich Ataxia studies →

Open to participants now

18 of the 71 studies in Friedreich Ataxia with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: 7 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Friedreich Ataxia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to confirm the treatment effects of vatiquinone on the key measures of FA disease progression.

03

Conditions studied

  • Friedreich's Ataxia

Browse trials for

04

Who can participate

Ages eligible
7 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • mFARS ≥20 to ≤70 at Screening (4 weeks prior to Day 1) and Baseline (Day 1).
  • Must be ambulatory as defined by a E7 score of 4 or less on the USS at Screening and Baseline.
  • Documentation that participants reached maximum score on items E4, E5, and E3b on the USS of mFARS at Screening and Baseline.
  • FA diagnosis (homozygous for guanine-adenine-adenine [GAA] repeat expansion in intron-1 of the frataxin gene), confirmed and documented with GAA repeat length for both alleles by clinical genetic testing.
  • Difference in the mFARS score between Screening and Baseline of no more than 4 points.
  • Ability to abstain from strong cytochrome P450 (CYP) 3A4 inducers/inhibitors (for example, ketoconazole, rifampin, St. John's wort, grapefruit juice) for at least 4 weeks prior to Baseline and for the duration of the study.

Key Exclusion Criteria:

  • Individuals with clinical diagnosis of FA who have point mutations, deletions, or other non-GAA expansion mutations.
  • Allergy to vatiquinone, sesame oil, gelatin (bovine and/or porcine), titanium dioxide, or red iron oxide.
  • Pregnant or lactating participants or those sexually active participants who are unwilling to comply with proper methods; females of must have a negative pregnancy test at Screening and during the Baseline Visit.
  • Comorbidities that may confound study results (for example, fat malabsorption syndrome, other mitochondrial disorder) in the opinion of the investigator.
  • Participation in an interventional clinical study or received drug (other than SKYCLARYS® [omaveloxolone]) within 60 days prior to Screening. Participants may be screened after the exclusionary period of 60 days has passed.
  • Current use of omaveloxolone. Previous use of omaveloxolone will be allowed if:

    1. Use was less than 3 cumulative months and participants have been off treatment for >30 days.
    2. Use was less than 6 cumulative months and participants have been off treatment for >90 days
  • Previous or concurrent use of other investigational treatment for FA.
  • Participation in any cell or gene therapy-based treatment for FA.
  • Participation in an ongoing study for vatiquinone or current or previous use of vatiquinone.
  • Illicit drug use 30 days prior to Screening and during the study.

Note: Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Vatiquinone

    Participants will receive vatiquinone capsule at a dose of either 200 milligrams (mg) orally 3 times a day (TID) if weighing ˂25 kilograms (kg) or 400 mg orally TID if weighing ≥25 kg for 24 months.

    Drug: Vatiquinone

Interventions

  • Vatiquinone will be administered per dose and schedule specified in the arm.

    Also known as: PTC743

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Modified Friedreich's Ataxia Rating Scale (mFARS) Score at Month 24

    Time frame: Baseline, Month 24

Secondary outcomes

  1. Change From Baseline in mFARS Subscale Scores (Upright Stability Subscale [USS], Upper Limb [UL], Lower Limb [LL], Bulbar [BUL]) at Month 24

    Time frame: Baseline, Month 24

  2. Change From Baseline in Friedreich's Ataxia Rating Scale - Activities of Daily Living (FARS-ADL) Score at Month 24

    Time frame: Baseline, Month 24

  3. Change From Baseline in 25-Foot Walk Test (T25FW) at Month 24

    Time frame: Baseline, Month 24

  4. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline up to Month 25

07

Study locations

9 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Mar 2029, 31 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Jul 2, 2026
StartEst.
Aug 15, 2026
Primary completionEst.
Mar 15, 2029
CompletionEst.
Mar 15, 2029
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07681713
Lead sponsor
PTC Therapeutics
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Aug 15, 2026 (estimated)
Primary completion
Mar 15, 2029 (estimated)
Completion
Mar 15, 2029 (estimated)
Last update
Aug 14, 2026

Study contacts

Patient Advocacy
Contact
medinfo@ptcbio.com
1-866-562-4620

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha-tocotrienol quinone

Start the discussion